Liu Meng, Zhang Fuxian
Department of Vascular Surgery, Beijing Shijitan Hospital, Capital Medical University, Beijing 100038, China; Department of Vascular Surgery, Tianjin Hospital, Tianjin 300211, China.
Department of Vascular Surgery, Beijing Shijitan Hospital, Capital Medical University, Beijing 100038, China.
Stem Cells Int. 2016;2016:4035307. doi: 10.1155/2016/4035307. Epub 2016 Jan 5.
Kissing-stenting treatment has been used to treat patients with peripheral artery disease (PAD). However, the long term efficacy of the stenting therapy is not well defined in Chinese PAD patients. To investigate the question, sixty-three PAD patients (37 males and 26 females), aged 66 ± 7.3 years, were analysed in the study. They were featured as claudication (n = 45, 71.4%), rest pain (n = 18, 28.6%), or gangrene (n = 8, 12.7%). In total, 161 stents were applied in aorta-iliac lesions with 2.6 stents for each patient, including 55 self-expanding stents, 98 balloon expandable stents, and 8 covered stents. The success rate of implanting Kissing-stents was 100%. Catheter-directed thrombolysis (CDT) with urokinase was performed in 8 cases (12.7%). The severity of peripheral ischemia was significantly improved, as evidenced by 3.3-fold increase of ankle-brachial pressure index (ABI) after the surgery (P = 0.008). One, three, five, and seven years after surgery, the primary patency rate was 87.3%, 77.4%, 71.1%, and 65.0%, whereas the secondary patency rate was 95.2%, 92.5%, 89.5%, and 85.0%, respectively. No in-hospital mortality was recorded. In conclusion, Kissing-stenting technique for aorta-iliac lesions is safe and effective with lower complications. It is beneficial for aorta-iliac occlusions that are longer than 60 mm.
吻合支架治疗已用于治疗外周动脉疾病(PAD)患者。然而,在中国PAD患者中,支架治疗的长期疗效尚不明确。为研究该问题,本研究分析了63例PAD患者(男性37例,女性26例),年龄66±7.3岁。他们的特征为间歇性跛行(n = 45,71.4%)、静息痛(n = 18,28.6%)或坏疽(n = 8,12.7%)。总共161枚支架应用于主-髂动脉病变,每位患者平均植入2.6枚支架,其中包括55枚自膨式支架、98枚球囊扩张式支架和8枚覆膜支架。吻合支架植入成功率为100%。8例(12.7%)患者接受了尿激酶导管定向溶栓(CDT)治疗。外周缺血严重程度显著改善,术后踝肱压力指数(ABI)增加了3.3倍(P = 0.008)。术后1年、3年、5年和7年,主要通畅率分别为87.3%、77.4%、71.1%和65.0%,而次要通畅率分别为95.2%、92.5%、89.5%和85.0%。无院内死亡记录。总之,主-髂动脉病变的吻合支架技术安全有效,并发症较少。对于长度超过60毫米的主-髂动脉闭塞有益。